Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy, but the efficacy of rifaximin in NASH patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Jian, Jie, Nie, Mei-Tong, Xiang, Baoyu, Qian, Hui, Yin, Chuan, Zhang, Xin, Zhang, Menghui, Zhu, Xuan, Xie, Wei-Fen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017645/
https://www.ncbi.nlm.nih.gov/pubmed/35450049
http://dx.doi.org/10.3389/fphar.2022.841132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017645/
https://www.ncbi.nlm.nih.gov/pubmed/35450049
http://dx.doi.org/10.3389/fphar.2022.841132

Ejemplares similares